Brandi Wiens, MD
Adult Medicine · Andover, KSNPI 1962848085
Payments from drug & device makers
Across 162 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$319
- Pfizer$272
- Novo Nordisk$257
- Amgen$233
- Trice Medical, Inc.$195
- Vanda Pharmaceuticals Inc.$137
- plus $1K from 34 others
What the payments were for
- Food & beverage$2,907100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $319 |
| Pfizer | 20 | $272 |
| Novo Nordisk | 17 | $257 |
| Amgen | 17 | $233 |
| Trice Medical, Inc. | 1 | $195 |
| Vanda Pharmaceuticals Inc. | 4 | $137 |
| Bayer | 9 | $133 |
| Lilly USA, LLC | 7 | $129 |
| GSK | 6 | $109 |
| AbbVie | 6 | $107 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $103 |
| Otsuka America Pharmaceutical, Inc. | 4 | $90 |
| Lundbeck LLC | 4 | $69 |
| Merck | 4 | $61 |
| Verona Pharma, Inc. | 3 | $59 |
| Ardelyx, Inc. | 3 | $57 |
| Dexcom, Inc. | 3 | $55 |
| Insulet Corporation | 3 | $45 |
| Paratek Pharmaceuticals, Inc. | 2 | $44 |
| E.r. Squibb & Sons, L.L.C. | 2 | $43 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Sumitomo Pharma America, Inc. | 2 | $35 |
| Boehringer Ingelheim | 2 | $31 |
| Vertex | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Sanofi Pasteur Inc. | 2 | $25 |
| Abbott | 1 | $23 |
| Astellas Pharma US Inc | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Novartis | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Medtronic | 1 | $14 |
| Organon | 1 | $13 |
| Neos Therapeutics, LP | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $12 |
| Veran Medical Technologies, Inc. | 1 | $10 |
How this compares
Too few adult medicine providers in Kansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 120 | $129,011 |
| TrulicityDulaglutide | 21 | $44,253 |
| OzempicSemaglutide | 33 | $35,934 |
| EliquisApixaban | 45 | $32,035 |
| JanuviaSitagliptin Phosphate | 26 | $32,033 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $29,154 |
| FarxigaDapagliflozin Propanediol | 32 | $25,406 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $24,120 |
| MounjaroTirzepatide | 15 | $17,669 |
| TradjentaLinagliptin | 18 | $13,397 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $11,752 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $11,731 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 66 | $11,659 |
| XareltoRivaroxaban | 12 | $10,666 |
| MyrbetriqMirabegron | 12 | $10,001 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $31 | $142,409138 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $129 | $61,92136 claims |
| AstraZenecaFarxiga, Symbicort | $319 | $37,15871 claims |
| Novo NordiskOzempic | $257 | $35,93433 claims |
| PfizerEliquis | $272 | $32,03545 claims |
| MerckJanuvia | $61 | $32,03326 claims |
| AbbVieUbrelvy, Synthroid | $107 | $10,45522 claims |
| Astellas Pharma US IncMyrbetriq | $20 | $10,00112 claims |
| GSKBreo Ellipta | $109 | $7,81621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult medicine providers in Kansason file to place this against a meaningful peer group, so we don't.
Other adult medicine in Andover
- Curtis WolfeLawrence$2K
- David SmithOverland Park$194
- Alice NjorogeOlathe$84
- Rebecca ClaryLenexa$14
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.